Factors Prognostic for Survival in Japanese Patients Treated with Sunitinib as First-line Therapy for Metastatic Clear Cell Renal Cell Cancer

Kawai, Y; Osawa, T; Kobayashi, K; Inoue, R; Yamamoto, Y; Matsumoto, H; Nagao, K; Hara, T; Sakano, S; Nagamori, S; Matsuyama, H

추천

검색

자료유형: 학술저널

저자정보: Kawai, Y (Department of Urology, Graduate School of Medicine, Yamaguchi University) Osawa, T (Department of Urology, Hokkaido Cancer Center) Kobayashi, K (Department of Urology, Graduate School of Medicine, Yamaguchi University) Inoue, R (Department of Urology, Graduate School of Medicine, Yamaguchi University) Yamamoto, Y (Department of Urology, Graduate School of Medicine, Yamaguchi University) Matsumoto, H (Department of Urology, Graduate School of Medicine, Yamaguchi University) Nagao, K (Department of Urology, Graduate School of Medicine, Yamaguchi University) Hara, T (Department of Urology, Graduate School of Medicine, Yamaguchi University) Sakano, S (Department of Urology, Graduate School of Medicine, Yamaguchi University) Nagamori, S (Department of Urology, Hokkaido Cancer Center) Matsuyama, H (Department of Urology, Graduate School of Medicine, Yamaguchi University)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제16권 제14호

발행연도: 2015.1

수록면: 5,687 - 5,690 (4page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: Factors predictive of survival have been identified in Western patients with metastatic clear cell renal cell carcinoma (mCCRCC) treated with sunitinib. Less is known, however, about factors predictive of survival in Japanese patients. This study evaluated factors prognostic of survival in Japanese patients with mCCRCC treated with first-line sunitinib. Materials and Methods: This retrospective study evaluated 46 consecutive Japanese mCCRCC patients treated with sunitinib as first line therapy. Clinical and biochemical markers associated with progression-free survival (PFS) were analyzed, with prognostic factors selected by uniand multivariate Cox regression analyses. Results: Univariate analysis showed that factors significantly associated with poor PFS included Memorial Sloan-Kettering Cancer Center poor risk scores, International Metastatic RCC Database Consortium poor risk and high (>0.5 mg/dl) serum C-reactive protein (CRP) concentrations (p<0.001 each). Multivariate analysis showed that high serum CRP was independently associated with poorer PFS (p=0.040). Six month disease control rate (complete response, partial response and stable disease) in response to sunitinib was significantly higher in patients with normal (${\leq}0.5mg/dl$) than elevated baseline CRP (p<0.001). Conclusions: CRP is a significant independent predictor of PFS for Japanese patients with mCCRCC treated with first-line sunitinib. Pretreatment CRP concentration may be a useful biomarker predicting response to sunitinib treatment.

#Metastatic renal cell carcinoma #sunitinib #prognosis

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!